does semaglutide oral work drops: the complete guide to sublingual GLP-1 dosing A Pharmacological and Clinical Overview

The mean follow-up on-treatment was 181 days (median 155 days, IQR 71 to 290 days) for tirzepatide initiators and 174 days (median 148 days, IQR 82 to 254 days) for semaglutide initiators

GLP-1 has been shown to have a range of benefits, including: Improved blood sugar control Weight loss Cardiovascular risk reduction Improved quality of life Reduced risk of hypoglycemia Easy to use GLP-1 is administered once a week via a subcutaneous injection, making it a convenient option for individuals who may have difficulty adhering to daily medication regimens

Tirzepatide in addition to being a GLP-1 receptor agonist like Semaglutide, it also is a GIP receptor agonist and increases energy expenditure resulting in weight loss

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al